Zydus Lifesciences Q1 FY27 Earnings Call Transcript Released; Consolidated Revenue Up 22%
Zydus Lifesciences reported Q1 FY27 consolidated revenues of ₹80.2 billion (up 22% YoY), with EBITDA at ₹19.3 billion and net profit at ₹9.4 billion. The company reaffirmed its guidance for strong double-digit growth for FY27. Key developments include the US launch of its first biosimilar, NufymcoTM, and the acquisition of Assertio Holdings. The branded portfolio now constitutes over 55% of revenue, with a medium-term target of over two-thirds.
The announcement includes significant financial results, strategic acquisitions, new product launches in key markets like the US, and updates on clinical trials, all of which have a substantial impact on the company's future growth and market position.
The company reported strong year-on-year growth in consolidated revenues and profits, along with positive operational highlights and strategic advancements, indicating a favorable financial and business outlook.
Zydus Lifesciences Limited has released the transcript of its Q1 FY27 post-results earnings call, which was held on August 11, 2026. The company reported strong double-digit growth for the quarter, building on the previous fiscal year's performance. Consolidated revenues stood at ₹80.2 billion, marking a 22% year-on-year increase. The company achieved an EBITDA margin of 24.1%, with EBITDA for the quarter at ₹19.3 billion and net profit at ₹9.4 billion. The net debt to EBITDA ratio was reported at 0.7 times as of June 30, 2026.
The pharmaceutical business in India saw its branded formulations grow by 20% year-on-year, outperforming the market across various therapy areas. The international formulations business also demonstrated robust growth, with revenues of ₹9.7 billion, a 34% year-on-year increase. The North America business, including the US and Canada, reported revenues of ₹31 billion, a 5% quarter-on-quarter increase. Key developments in the US included the filing of 5 ANDAs, approval of 9 ANDAs, and the launch of 11 new products. The company also launched its first biosimilar in the US market, NufymcoTM Injection (Ranibizumab), and completed the acquisition of Assertio Holdings.
The Consumer Wellness business recorded revenues of ₹14.3 billion, a significant 67% year-on-year increase, driven by both domestic and international segments. The medical devices business generated ₹2.8 billion in revenues. Operationally, the injectable manufacturing facility at Zydus Biotech Park received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification. Additionally, the company entered into a joint venture with Sunshine Healthcare to establish a pharmaceutical manufacturing facility in Sri Lanka.
Dr. Sharvil Patel, Managing Director, highlighted the company's transformation into an innovation-led organization, with the branded portfolio contributing over 55% of total revenue in Q1 FY27, a share expected to exceed two-thirds in the medium term. The company maintained its guidance for strong double-digit growth for the full fiscal year. Discussions also covered the US specialty business, including the acquisition of Rolvedon®, the NDA submission for Saroglitazar, and the potential market opportunity for Saro in the $200-$300 million range, potentially exceeding $400 million. The company anticipates significant scaling up of its US specialty business around calendar year 2029. Updates were also provided on clinical trials for Saroglitazar Magnesium, Desidustat, and Usnoflast.
What to do with a filing like this
Zydus Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zydus Lifesciences Limited. Read the original for the full detail.